Strategies and End Points in the Development of Novel Immunotherapy Trials for Patients With Unresectable, Locally Advanced Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Strategies and End Points in the Development of Novel Immunotherapy Trials for Patients With Unresectable, Locally Advanced Non–Small-Cell Lung Cancer

Published:2022-10-10 Issue:29 Volume:40 Page:3353-3356
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Pennell Nathan A.¹^ORCID

Affiliation:

1. Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.22.00827

Reference18 articles.

1. Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non–Small-Cell Lung Cancer

2. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

3. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

4. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer

5. Monalizumab: inhibiting the novel immune checkpoint NKG2A

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis;The Lancet Oncology;2024-04

2. Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer;Pharmaceutics;2023-04-16